Company Filing History:
2 out of 114 
1 out of 1 Years Active: 1986-1989
Title: Keishin Sugahara: Innovator in Hepatitis B Antigen Purification
Introduction
Keishin Sugahara is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of biotechnology, particularly in the purification of hepatitis B antigens. With a total of 3 patents to his name, Sugahara's work has implications for vaccine development and therapeutic applications.
Latest Patents
Sugahara's latest patents include a method for the purification of HBc antigen and a method for measuring HBc antibody. The purification method involves subjecting a solution containing HBc antigen to acid treatment, followed by ion exchange chromatography. This innovative approach allows for the effective removal of lipid and contaminant proteins, resulting in a highly purified HBc antigen. Additionally, his method for measuring HBc antibody utilizes the purified HBc antigen in various immunoassay techniques, including passive hemagglutination, EIA, and RIA methods. Another significant patent focuses on the purification of HBs antigen, which is crucial for large-scale hepatitis B vaccine production. This method employs adsorption chromatography and gel filtration to achieve a high purity level of HBs antigen.
Career Highlights
Throughout his career, Sugahara has worked with esteemed organizations such as the Chemo-Sero-Therapeutic Research Institute. His expertise in recombinant DNA technology has positioned him as a key figure in the development of methods that enhance the production and purification of vital antigens.
Collaborations
Sugahara has collaborated with notable colleagues, including Fukusaburo Hamada and Nobuya Ohtomo. These partnerships have contributed to the advancement of research in the field of hepatitis B and related therapies.
Conclusion
Keishin Sugahara's innovative work in the purification of hepatitis B antigens has made a significant impact on vaccine development. His patents reflect a commitment to advancing biotechnology and improving public health outcomes.